Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activating and resistance mutations of the epidermal growth factor receptor (EGFR) gene and non-small cell lung cancer: a clinical reality.

Archivos de bronconeumologia - 1 Feb 2011

Taus Alvaro, Vollmer Iván, Arriola Edurne

Abstract excerpt

In non-small cell lung cancer, the EGFR gene mutations identify a patient sub-population with different clinical characteristics and treatment responses to those that do not have these mutations. There are mutations that derive in increased sensitive to EGFR targeted therapy, as well as mutations that result in resistance. The determination of EGFR mutations involves a change in the therapeutic approach to lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 20678850
DOI: 10.1016/j.arbres.2010.06.013

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activating and resistance mutations of the epidermal growth factor receptor (EGFR) gene and non-small cell lung cancer: a clinical reality.PMID 20678850Read ↗

Epidermal Growth Factor Receptor targeting in non-small cell lung cancer: revisiting different strategies against the same target.Semantic proximity Read ↗

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.Semantic proximity Read ↗

Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.Semantic proximity Read ↗

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A ReviewSemantic proximity Read ↗

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsSemantic proximity Read ↗

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.Semantic proximity Read ↗

Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.Semantic proximity Read ↗

Review. EGFR mutations in non-small cell lung cancer--clinical implications.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.